Compare LUNG & LFVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LUNG | LFVN |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.1M | 78.0M |
| IPO Year | 2020 | 1996 |
| Metric | LUNG | LFVN |
|---|---|---|
| Price | $1.96 | $6.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $5.38 | ★ $11.00 |
| AVG Volume (30 Days) | ★ 342.0K | 47.4K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.56% |
| EPS Growth | ★ 7.64 | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | $90,497,000.00 | ★ $203,204,000.00 |
| Revenue This Year | $2.48 | N/A |
| Revenue Next Year | $18.46 | N/A |
| P/E Ratio | ★ N/A | $15.45 |
| Revenue Growth | ★ 8.01 | 1.86 |
| 52 Week Low | $1.13 | $3.90 |
| 52 Week High | $2.89 | $11.71 |
| Indicator | LUNG | LFVN |
|---|---|---|
| Relative Strength Index (RSI) | 42.05 | 42.52 |
| Support Level | $1.20 | $5.73 |
| Resistance Level | $2.16 | $6.89 |
| Average True Range (ATR) | 0.15 | 0.37 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 12.26 | 32.65 |
Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of in the United States, Mexico, Canada, Japan, Taiwan, Thailand, Australia, New Zealand, the United Kingdom, the Netherlands, Germany, Austria, Spain, Ireland, Belgium, and Others. The company operates in a single operating segment by selling products directly to customers through an international network of independent consultants that operate in an integrated manner.